Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02238496 · ClinicalTrials.gov registry record · Phase 1
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
A Phase 1 study, sponsored by Andrew B Lassman, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02238496 is a Phase 1 study that has completed, run by Andrew B Lassman, MD. The registered enrollment target is 10 participants.
The verdict
NCT02238496, a Phase 1 study, has completed, sponsored by Andrew B Lassman, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors. Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow. Research suggests that combined treatment with both drugs is better than either alone, and that it is reasonably safe.
Interventions
- DRUG Temsirolimus
- PROCEDURE Cytoreductive surgery
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-12-08 |
| Est. Completion | 2021-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02238496
The ClinicalTrials.gov registry entry for NCT02238496 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew B Lassman, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temsirolimus is the first listed.
NCT02238496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02238496 about?
NCT02238496 is a clinical study titled "Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas". The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kid...
What is the current status of trial NCT02238496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-12-08. Estimated completion is 2021-02-14.
What interventions are being tested in trial NCT02238496?
The interventions under investigation include: Temsirolimus (DRUG), Cytoreductive surgery (PROCEDURE), Perifosine (DRUG).
Who is sponsoring clinical trial NCT02238496?
This trial is sponsored by Andrew B Lassman, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.